RAPP Stock Forecast & Price Target

Rapport Therapeutics is attractive because it has already established proof of concept for RAP-219 in both focal onset seizures and bipolar mania, while the mania Phase 2 showed statistically significant benefit on YMRS and CGI-BP with tolerability near placebo and no serious adverse events. Its balance sheet also looks strong after raising about $420.7M in October/November 2026, lifting pro-forma cash to $815.4M and extending runway to YE29, which supports planned Phase 3 work in PGTCS and bipolar mania. The company also has meaningful optionality from discovery-stage nAChR programs in chronic pain and hearing disorders, making the pipeline broader than a single asset despite a 3Q26 net loss of $40.2M.

Rapport Therapeutics is a clinical-stage biotechnology company whose value depends heavily on RAP-219 and two discovery-stage nAChR programs, but this concentration leaves the stock vulnerable to any failure in focal onset seizures, primary generalized tonic-clonic seizures, or bipolar mania. The bearish case is strengthened by clear downside risks already flagged, including trial misses, unexpected safety or tolerability signals, clinical and regulatory delays, step-therapy positioning, and broader R&D or commercial setbacks, any of which could severely impair future pipeline value. With no established revenue base and financing risk remaining until cashflow positive, the company may need additional capital before meaningful de-risking, while new competitors could further pressure its long-term opportunity.